Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colquhounia root tablets for type 2 diabetes mellitus with chronic kidney disease
ChiCTR2300077605Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of colquhounia root tablet in diabetic glomerulosclerosis, type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by Peking University First Hospital. Primary endpoint: Change in urinary albumin-creatinine ratio at 6 months. Started Dec 2022; status: recruiting.
02
Drugs
colquhounia root tablet
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2300077605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077605.